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Introduction
Oromandibular dystonia (OMD) is a movement disorder characterized by
involuntary, repetitive, and patterned muscle contractions of varying severity,
affecting the jaws, tongue, face and pharynx.1 It usually manifests as muscle
contraction with repetitive movement, abnormal postures and a wide variation
in clinical presentation- depending on the musculature affected.2
Dystonia can be classified into regions of distribution: Focal, segmental,
multifocal and generalized. It can also be primary or seconday based on aetiology
(see table 1).
Table 1.
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The most common secondary type is tardive dystonia, which develops as a side
effect of long term treatment with antipsychotic drugs. Oro-facial-lingual
stereotypes are more frequent in the tardive than the idiopathic group, which is
often associated with cervical dystonia.3
The clinical characteristic of the dystonia may be classified as jaw opening, jaw
closing, jaw deflecting, jaw retruding or a mixed/combination type. The
differential diagnoses for OMD include temporomandibular joint disorders,
hemifacial spasm and psychological disorders. When OMD occurs with
blepharospasm it is known as Meiges syndrome.
Patients have reported triggers such as stress, talking, chewing and praying.
There are some learned behaviours that help reduce the dystonia such as
sleeping, relaxing, talking, singing, lip biting, tongue posturing, swallowing and
chewing.4
Oral medication is often the first line of treatment as systemic pharmacologic
therapy benefits about 30% of patients.2 Although most oral medications have a
low success rate, treatment includes cholinergics, benzodiazepines, anti-
parkinsonism drugs, anti-convulsants, baclofen, carbamazepine and lithium.
Anticholinergic medications have been found to be the most effective oral
medication for the treatment of dystonia. Muscle afferent block (MAB) has been
found to be highly effective for OMD but has no effect in patients with dyskinetic
symptoms.5MAB involves intramuscular injection of anaesthetic and alcohol and
has been used for the treatment of OMD. However, since it is not as effective with
dyskinetic symptoms, this suggests that OMD and oral/orofacial dyskinesia may
have a different physiopathology.
The next line of treatment is Botulinum toxin injections which are the mainstay
of treatment for most focal dystonias. The response rate has been reported as
high as 90-95% with Botulinum toxin type A.6 However, some patients can
become secondarily nonresponsive as Botulinum neurotoxins may be
immunogenic leading to immuno-resistance.
Jaw closing dystonia responds better than jaw opening or mixed dystonia. The
treatment of the latter types of OMD is more likely associated with dysphagia
and dysarthria.
Method
A literature review was undertaken. The patients treated for OMD were
identified in a specific period from 2013-2015. These cases were analysed with a
data collection tool. The outcome was measured using the Glasgow Benefit
Inventory (GBI) score. This is a questionnaire used to measure the change in
health status produced by the intervention. There are 18 items and it is intended
for use on adults- representing a measure of patient-reported outcome. It is a
subjective patient oriented post-interventional questionnaire which is sensitive
to any change in health status brought about by a specific event- in this case the
administration of Botulinum toxin to treat OMD. GBI scores can range from -100
(maximal adverse effect), through 0 (no effect), to 100 (maximal positive effect).
Results
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The results of the literature review are summarized in table 2. One study using
the GBI questionnaire showed a mean score of +38.04.7 Overall, there was a
positive beneficial result with Botulinum toxin treatment.
In our experience, there were 6 patients treated for OMD with Botulinum toxin
type A. The results are summarized in table 3. The mean dose of toxin delivered
to the various muscles: masseter, temporalis, lateral pterygoid, anterior digastric
and genioglossus were 20, 15, 24, 15 and 20 units respectively to each side.
The overall GBI score was positive for all except one patient. Further analysis of
the GBI score reflected that patients improved in the sub-categories of general
well being, social and physical outcomes (see table 3). The mean GBI score was
+40. The mean improvement in the categories of general health, social health
and physical health were 82.17%, 37.17% and 31.17% respectively.
Author, year Number
of
patients
Diagnosis Treatment
given
Outcomes Complications
Moscovich et al,
2015
8 Open jaw/jaw
deviation
dystonia
Onabotulinum
toxin using
internal
approach
-6 patients very
much improved
-2 patients much
improved
(Global Impression scale)
One adverse event-
nasal speech
following injection
Jankovic et al,
2015
1046 Cervical
dystonia
189.8 ±87.1
Units Botulinum
toxin, average
treatment
interval 14.6 and
15.1 weeks
-Score decreased
from 39.2 to 27.1
(Toronto Western
Spasmodic Torticollis Rating
Scale)
-Score improved
from 91.2% to 95%
(Clinical Global Assessment
of change)
-Score improved
from 83% to 91.7%
(Clinical Global Assessment
of change)
-Reduction in
cervical dystonia
impact profile
-26.2% reported
adverse events
-7.0%muscle
weakness
-6.4% dysphagia
Pedemonte et
al, 2015
30 Post traumatic
OMD
Onabotulinum
Toxin A
Symptoms better in
all cases
N/A
Teive et al,
2012
5 Jaw opening
OMD secondary
to Wilsons
Disease
Botulinum toxin
type A
Dystonia score
partially reduced 3
weeks after injection
Mild dysphagia
Bhattacharyya
et al, 2001
23 -5 with OMD
-18 with
Spasmodic
Dysphonia
Botulinum Toxin -Mean score +38.04
-OMD group derived
smaller benefit
(Glasgow Benefit Inventory
Score)
N/A
Tan et al,
1999
162 OMD -54.2±15.2
Units to
masseter
-
28.6±16.7Units
to submentalis
-Mean global effect
was 3.01 ±1
(4=complete abolition of
dystonia)
-31.5% reported
adverse effects
-11.1% had
dysphagia or
dysarthria
Table 2.7,8,9,10,11,12
Case 1.
This patient was a 56 year old woman with a background of hypertension. She
was diagnosed with a 3-4 year history of oromandibular dystonia characterized
by increased mandibular movements affecting speech and mastication. The drug
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history included prochlorperazine. Despite stopping this drug, symptoms
persisted. Movements were a combination of jaw closing and jaw deflecting
types. Over the course of a year, she received 3 courses of treatment with
Botulinum toxin and is planned for ongoing treatment. After treatment, outcome
measures show improvement in all categories.
Case 2.
This 45 year old diabetic woman presented with a history of chronic bilateral
temporomandibular joint dislocations. Initial treatment with Botulinum toxin to
the lateral pterygoid muscles arrested the dislocations but the patient developed
a jaw retruding oromandibular dystonia. Treatment to the muscles of
mastication resulted in alleviation of symptoms. The patient reported a negative
overall benefit though she reported improvement in all categories. This case
illustrates the difficulties in diagnosing OMD but it also show the versatility of
Botulinum toxin treatment.
Case 3.
This 82 year old woman presented with OMD characterized by involuntary
contractions of masseter, temporalis, digastric and the pterygoid muscles. She
also had involuntary tongue movements. The treatment of the muscles of
mastication was successful but the tongue movements remained an issue until
the genioglossus muscle was treated. Because of her tendency for bruxism, the
intraoral treatment of the lateral pterygoid muscles was difficult and an
extraoral approach was used. The patient reported significant benefit from
treatment. This was a mixed /combination type of OMD.
Case 4.
This 77 year old woman presented with OMD of the jaw deflecting type. She had
a background of paroxysmal atrial fibrillation, hypertension and hypothyroidism.
She was on warfarin treatment. The lateral pterygoid muscles were targeted for
Botulism toxin treatment using an intraoral approach. The patient reported
improvement in all categories.
Case 5.
This 57 year old man presented with a 4 year history of OMD with
blepharospasm and was diagnosed with Meiges syndrome. He had a
combination type of OMD characterized by jaw opening and jaw deflecting
movements. Treatment was successful as reflected in the patient GBI score.
Case 6.
This 45 year old woman presented with OMD characterized by lateral and
protrusive movements of the mandible. Therefore she was diagnosed with a
mixed/combination type OMD. Patient admitted to a history of using
mephedrone (M-CAT). The outcome measures show improvement in all
categories.
Br J Oral Maxillofac Surg. 2016 Dec;54(10):1080-1084. doi:
10.1016/j.bjoms.2016.06.028.
Case Features Treatment GBI outcome
1 -Increased speed of involuntary
posterior mandibular movements
during mastication
-Increased lisp during speech
-25U to both Masseter m.
-25U to both Temporalis m.
Overall +55
General 92%
Social 30%
Physical 33%
2 -Chronic bilateral TMJ dislocation -20U to both Masseter m.
-20U to L. Pterygoid m.
-10U to both Temporalis m.
Overall -11
General 57%
Social 37%
Physical 17%
3 -Bruxism
-Movements of mandible and
tongue
-25U to both L. Pterygoid m.
-20U to both Genioglossus m.
Overall +63
General 93%
Social 43%
Physical 37%
4 -Lateral mandibular movements -25U to both L. Pterygoid m. Overall +72
General 98%
Social 47%
Physical 40%
5 -Meige Syndrome
-Lateral mandible movements
-Progressive opening
-Blepharospasm
-Upper right limb postural tremor
-25U to both L. Pterygoid m.
-15U to both Ant. Digastric m.
Overall +22
General 72%
Social 33%
Physical 30%
6 -Lateral and protrusive
mandibular movement
-25U to both L. Pterygoid m.
-15U to both Masseter m.
-10U to both Temporalis m.
Overall +39
General 81%
Social 33%
Physical 30%
Table 3.
Discussion.
The results from the study were in keeping with previously published outcomes.
Therefore, our experience further demonstrates that Botulinum toxin type A is
an effective treatment for OMD with minimal complications.
OMD is often misdiagnosed and medical treatment is sometimes ineffective. The
use of Botulinum toxin has proven to be an effective and easy treatment with
only a few complications reported. Botulinum toxin type A blocks the release of
acetylcholine at the presynaptic junction, producing a transient weakening of the
muscle activity without systemic effects. It also has the advantage of being used
with electromyography (EMG) guidance which permits individual treatment
plans with lower doses than with conventional treatment. Although, OMD can
cause considerable functional and psychological disability to the patient,
injection with Botulinum Toxin type A is a safe and simple treatment option
which is highly effective compared with other therapies.
In our experience, injecting the Botulinum toxin into the lateral pterygoid muscle
can prove difficult in OMD cases where there is a high frequency movement or a
wide displacing movement of the mandible. Therefore, to overcome this, an
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extraoral approach was used where the needle was directed through the sigmoid
notch as illustrated in figure 1.
The cases highlighted have shown the successful treatment for the different
types of OMD, including Meiges syndrome using Botulinum toxin type A. Also
illustrated was the use of this treatment for chronic dislocation of the
temporomandibular joints.
This case series outlines Botulinum toxin type A as a simple but effective
treatment for all types of OMD. Its versatility lends itself to treatment of
mostconditions involving muscular spasms and the resulting ataxia and
dysfunction.
Figure 1.
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